2nd Global Pediatric Ophthalmology Congress

The purpose is to describe the long-term outcomes of intravitreal bevacizumab (IVB) for the treatment of pediatric retinal and choroidal diseases. We performed a retrospective analysis of all pediatric patients receiving IVB at our HHC facilities for retinal and choroidal disease. We analyzed the data for visual acuity, stabilization of disease process and central macular thickness for 1 year. Safety data (adverse events) were analyzed. All eyes receiving IVB for the following were included in this analysis: Sickle cell retinopathy, Coats disease, familial exudative vitreoretinopathy (FEVR), SRNM (secondary to trauma, myopia) and CME secondary to uveitis of various etiologies. IVB was used both as a primary treatment and in combination with other options. Patients receiving IVB for ROP were analyzed separately. Patients receiving IVB for pediatric retinal and choroidal disease tolerated the treatment well. Most patients experienced significant improvement or stabilization of vision but long term safety concerns still remains.